Few outcome measures were validated for assessing depressive symptoms in AD. Patient Health Questionnaire-9 (PHQ9) and the abridged PHQ2 are established patient-reported outcome measures of depressive symptoms.
Objective
We sought to examine the measurement properties of PHQ9 and PHQ2 in adult AD. A prospective dermatology-practice based study of 458 AD patients (age 18–97 years) was conducted.
Results
PHQ9 strongly correlated with Dermatology Life Quality Index, Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Disturbance and Sleep-Related Impairment, and PROMIS Itch Questionnaire Mood and Sleep (PIQ-MS), and moderately correlated with Patient-Oriented Eczema Measure, Numeric Rating Scale (NRS) average-itch, NRS-sleep, Eczema Area and Severity Index, Scoring AD and Rajka-Langeland scores. PHQ2 had significantly weaker correlations than PHQ9 with PROMIS SD, SRI and PIQ-MS, but similar correlations with other outcomes. PHQ9 and PHQ2 had good discriminant validity. Changes from baseline in PHQ9 and PHQ2 were poorly or weakly correlated with changes of the other outcome measures. There was no differential item functioning of PHQ items. PHQ9 showed good reliability (intraclass correlation coefficient range: 0.80–0.87). PHQ2 had slightly lower reliability (0.76–0.82).
Conclusions
PHQ9 and PHQ2 had similar measurement properties, but PHQ2 was more feasible to assess depressive symptoms in AD.
Get full access to this article
View all access options for this article.
References
1.
YewYW, ThyssenJP, SilverbergJI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol, 2019; 80(2):390–401.
2.
SilverbergJI, MargolisDJ, BoguniewiczM, et al.Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol, 2019; 33(7):1341–1348.
3.
VakhariaPP, ChopraR, SacotteR, et al.Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol, 2017; 119(6):548–52.e3.
4.
SilverbergJI, GelfandJM, MargolisDJ, et al.Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract, 2019; 7(8):2699–2706.e7.
5.
FishbeinAB, VitaternaO, HaughIM, et al.Nocturnal eczema: review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. J Allergy Clin Immunol, 2015; 136(5):1170–1177.
6.
SilverbergJI.Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders. Clin Dermatol, 2017; 35(4):360–366.
7.
SilverbergJI, GargNK, PallerAS, et al.Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol, 2015; 135(1):56–66.
8.
SilverbergJI, SimpsonEL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol, 2013; 24(5):476–486.
9.
YuSH, AttarianH, ZeeP, et al.Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis, 2016; 27(2):50–58.
10.
ChengBT, SilverbergJI. Depression and psychological distress in US adults with atopic dermatitis. Ann Allergy Asthma Immunol, 2019; 123(2):179–185.
11.
PatelKR, ImmaneniS, SingamV, et al.Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol, 2019; 80(2):402–410.
12.
RonnstadATM, Halling-OvergaardAS, HamannCR, et al.Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol, 2018; 79(3):448–56.e30.
13.
SchmittJ, Buske-KirschbaumA, RoessnerV. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy, 2010; 65(12):1506–1524.
14.
YaghmaieP, KoudelkaCW, SimpsonEL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol, 2013; 131(2):428–433.
15.
SilverbergJI, GelfandJM, MargolisDJ, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol, 2019; 181(3):554–565.
16.
JaworekAK, JaworekM, Makara-StudzinskaM, et al.Depression and serum content of serotonin in adult patients with atopic dermatitis. Adv Exp Med Biol, 2020; 1271:83–88.
17.
VinnikT, KreininA, AbildinovaG, et al.Biological sex and IgE sensitization influence severity of depression and cortisol levels in atopic dermatitis. Dermatology, 2020; 236(4):336–344.
18.
SchonmannY, MansfieldKE, HayesJF, et al.Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunol Pract, 2020; 8(1):248–57.e16.
19.
EichenfieldLF, TomWL, ChamlinSL, et al.Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol, 2014; 70(2):338–351.
20.
SimpsonEL, Bruin-WellerM, FlohrC, et al.When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol, 2017; 77(4):623–633.
21.
KroenkeK, SpitzerRL, WilliamsJB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med, 2001; 16(9):606–613.
22.
KroenkeK, SpitzerRL, WilliamsJB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care, 2003; 41(11):1284–1292.
23.
GilbodyS, RichardsD, BrealeyS, et al.Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med, 2007; 22(11):1596–1602.
24.
PicardiA, AdlerDA, AbeniD, et al.Screening for depressive disorders in patients with skin diseases: a comparison of three screeners. Acta Derm Venereol, 2005; 85(5):414–419.
25.
HanifinJ, RajkaG. Diagnostic features of atopic eczema. Acta Derm Venereol, 1980; 92:44–47.
26.
VakhariaPP, ChopraR, SacotteR, et al.Validation of patient-reported global severity of atopic dermatitis in adults. Allergy, 2018; 73(2):451–458.
27.
SilverbergJI, Chiesa FuxenchZC, GelfandJM, et al.Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. Ann Allergy Asthma Immunol, 2018; 121(6):729–734.
28.
SilverbergJ, LaiJ, PatelK, et al.Measurement properties of the PROMIS Itch Questionnaire—itch severity assessments in adults with atopic dermatitis [published online February 27, 2020]. Br J Dermatol, 2020. doi: 10.1111/bjd.18978. [Epub ahead of print].
29.
CharmanCR, VennAJ, WilliamsHC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol, 2004; 140(12):1513–1519.
30.
BasraMK, FenechR, GattRM, et al.The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol, 2008; 159(5):997–1035.
31.
DesaiNS, PoindexterGB, MonthropeYM, et al.A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol, 2008; 59(2):234–244.
32.
SilverbergJI, LaiJS, VakhariaPP, et al.Measurement properties of the Patient-Reported Outcomes Measurement Information System Itch Questionnaire(R) (PIQ) item banks in adults with atopic dermatitis. J Am Acad Dermatol, 2020; 82(5):1174–1180.
33.
SilverbergJI, LaiJS, KantorRW, et al.Development, validation and interpretation of the PROMIS Itch Questionnaire: a patient-reported outcome measure for the quality of life impact of itch. J Invest Dermatol, 2020; 140(5):986–994.e6.
34.
LeiD, YousafM, JanmohamedS, et al.Validation of patient-reported outcomes information system sleep disturbance and sleep-related impairment in adult atopic dermatitis [published online February 4, 2020]. Br J Dermatol, 2020. doi: 10.1111/bjd.18920. [Epub ahead of print].
35.
HanifinJM, ThurstonM, OmotoM, et al.The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol, 2001; 10(1):11–18.
36.
ChopraR, SilverbergJI. Assessing the severity of atopic dermatitis in clinical trials and practice. Clin Dermatol, 2018; 36(5):606–615.
37.
ChopraR, VakhariaPP, SacotteR, et al.Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol, 2017; 140(6):1708–1710.e1.
38.
ChopraR, VakhariaPP, SacotteR, et al.Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol, 2017; 177(5):1316–1321.
39.
Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology, 1993; 186(1):23–31.
40.
RajkaG, LangelandT. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh), 1989; 144:13–14.
41.
SilverbergJI, LeiD, JanmohamedS, et al.Measurement properties of the Rajka-Langeland severity score in children and adults with atopic dermatitis. Br J Dermatol, 2020. doi: 10.1111/bjd.19159. [Epub ahead of print].
HandDJ, TillRJ. A simple generalisation of the area under the ROC curve for multiple class classification problems. Mach Learn, 2001; 45(2):171–186.
44.
MetzCE.Basic principles of ROC analysis. Semin Nucl Med, 1978; 8(4):283–298.
45.
TerweeCB, BotSD, de BoerMR, et al.Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol, 2007; 60(1):34–42.
46.
LimCR, HarrisK, DawsonJ, et al.Floor and ceiling effects in the OHS: an analysis of the NHS PROMs data set. BMJ Open, 2015; 5(7):e007765.
47.
KooTK, LiMY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med, 2016; 15(2):155–163.
48.
TerweeCB, MokkinkLB, KnolDL, et al.Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res, 2012; 21(4):651–657.
49.
SilverbergJI, GelfandJM, MargolisDJ, et al.Measurement properties of the Hospital Anxiety and Depression Scale used in atopic dermatitis in adults. J Invest Dermatol, 2019; 139(6):1388–1391.
50.
SchmittJ, LanganS, StammT, et al.Core outcome domains for controlled trials and clinical recordkeeping in eczema: International Multiperspective Delphi Consensus Process. J Invest Dermatol, 2011; 131(3):623–630.
51.
YuSH, SilverbergJI. Association between atopic dermatitis and depression in US adults. J Invest Dermatol, 2015; 135(12):3183–3186.
